Merck & Co. (MRK) has now started testing its experimental Covid-19 vaccine candidate V591 in healthy volunteers, according to a report from the Wall Street Journal.The Phase 1 / 2 trial, which will take place in Belgium with 260 enrolled subjects, was reported by Merck on a government database and confirmed by the company, says the Wall Street Journal.According to the publisher, Merck said that dosing in study subjects has begun, but did not provide further comment.Merck gained the rights to V591 via its May acquisition of Themis, an Austrian vaccine maker developing vaccines and therapies based on an innovative …read more
Source:: Yahoo Finance
